New Data on Two Anavex Alzheimer’s Drugs to be Unveiled at AD/PD 2015

NEW YORK, March 19, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system

Read More

Anavex to Participate in Phase 3 Clinical Trials Panel at AD/PD 2015

NEW YORK, March 17, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system

Read More

Athgo Will Host Sixth Global Innovation Forum “Athgothon” at the World Bank in Washington D.C. from August 12-14, 2015

Los Angeles, C.A. – March 16, 2015 – Since its founding in 2002, Athgo International (http://bit.ly/1x6c0n3) has been a major international force for change. Athgo offers a unique array of

Read More

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

NEW YORK, March 12, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system

Read More

Anavex to Present at Sigma-1 Receptors Symposium

NEW YORK, March 10, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)

Read More

Corporate Review and Seven Star Enterprises Explore Gold and Silver Investments

March 5, 2015 – Boca Raton, Florida — Many regard gold and silver as strong investment options to protect against inflation. Seven Star Enterprises International works to advise investors about

Read More